{"gene":"VRK3","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":2009,"finding":"Crystal structure of VRK3 reveals it cannot bind ATP due to residue substitutions in the binding pocket, is locked in a pseudoactive conformation, and conserves surface residue interactions that play architectural roles; its active site is degraded while surface regions show high conservation suggesting key protein–protein interactions.","method":"X-ray crystallography of VRK3 and VRK2; structural comparison and sequence conservation analysis","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with detailed active-site analysis and comparative structural validation","pmids":["19141289"],"is_preprint":false},{"year":2006,"finding":"VRK3 directly binds the dual-specificity phosphatase VHR and enhances its phosphatase activity toward phospho-ERK in the nucleus, thereby suppressing ERK activation; this enhancement is independent of VRK3's kinase activity, placing VRK3 as a phosphatase-activating scaffold upstream of ERK inactivation.","method":"Co-immunoprecipitation, in vitro phosphatase activity assays with recombinant VRK3, kinase-dead mutant analysis","journal":"Nature Cell Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vitro phosphatase assay with kinase-dead mutant, replicated in subsequent work","pmids":["16845380"],"is_preprint":false},{"year":2007,"finding":"VRK3 forms a protein complex with VHR and ERK in rodent tissues including testis; recombinant VRK3 added to tissue lysates specifically enhances VHR phosphatase activity (but not MKP3 activity), and the VHR–VRK3 complex represents the phosphatase-active form that regulates EGF-induced ERK signaling.","method":"Immunoprecipitation from adult tissue and embryo lysates, in vitro phosphatase activity assay with recombinant VRK3, co-localization","journal":"Biochimica et Biophysica Acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and in vitro phosphatase assay, single lab confirming earlier finding with tissue specificity data","pmids":["18035061"],"is_preprint":false},{"year":2015,"finding":"VRK3 phosphorylates the nuclear envelope protein BAF (Barrier-to-Autointegration Factor) on Ser4; this kinase activity depends on VRK3's N-terminal regulatory region absent from its crystal structure. VRK3-mediated BAF phosphorylation causes translocation of BAF from nucleus to cytoplasm, and VRK3 expression is elevated during interphase where it promotes cell cycle progression.","method":"In vitro kinase assay with phospho-specific detection, site-directed mutagenesis (Ser4), immunofluorescence localization, cell cycle analysis by flow cytometry, siRNA depletion","journal":"Biochimica et Biophysica Acta","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay with mutagenesis and localization readout, single lab","pmids":["25899223"],"is_preprint":false},{"year":2016,"finding":"CDK5 phosphorylates VRK3 at Ser108 under oxidative stress; phosphorylated VRK3 has increased affinity for VHR phosphatase, leading to enhanced VHR-mediated dephosphorylation of ERK and neuroprotection against H2O2-induced apoptosis. A non-phosphorylatable VRK3 mutant (S108A) fails to attenuate apoptosis.","method":"In vitro kinase assay (CDK5 phosphorylating VRK3), co-immunoprecipitation, phospho-specific antibodies, VRK3 mutant overexpression, siRNA knockdown in neurons","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay plus mutagenesis and functional readout, single lab","pmids":["27346674"],"is_preprint":false},{"year":2016,"finding":"VRK3 facilitates nuclear localization of HSP70 after glutamate-induced excitotoxicity; nuclear HSP70 enhances VHR phosphatase activity via direct protein–protein interaction (not chaperone activity), thereby suppressing excessive ERK activation. VRK3-deficient neurons showed impaired HSP70 nuclear localization and increased vulnerability to glutamate-induced apoptosis.","method":"Co-immunoprecipitation, subcellular fractionation, phosphatase activity assay, siRNA knockdown, NLS-fused HSP70 rescue experiments, VRK3-KO neurons","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical methods including Co-IP and phosphatase assay plus genetic KO confirmation, single lab","pmids":["27941812"],"is_preprint":false},{"year":2017,"finding":"VRK3 interacts with and regulates phosphorylation of XRCC5 (Ku80) and CCNB1 (Cyclin B1) as identified by affinity purification–mass spectrometry; VRK3 depletion in liver cancer cells affects S phase progression and G2/M entry and exit.","method":"Affinity purification coupled to LC-MS/MS interactomics, biochemical confirmation of interactions, flow cytometry cell cycle analysis, siRNA knockdown","journal":"Molecules and Cells","confidence":"Low","confidence_rationale":"Tier 3 / Weak — interactome screen with partial biochemical confirmation, single lab, limited mechanistic follow-up","pmids":["28927264"],"is_preprint":false},{"year":2017,"finding":"Ectopic expression of VRK3 reduces nuclear presence of CRY1, CRY2, PER2, and BMAL1 (but not CLOCK) in mammalian cells; a nuclear localization sequence mutant of VRK3 attenuates this effect. siRNA-mediated knockdown of VRK3 reduces amplitude and lengthens the period of cellular circadian bioluminescence rhythms.","method":"Fluorescence imaging of RFP-tagged clock proteins upon VRK3 overexpression, NLS-mutant VRK3, siRNA knockdown with bioluminescence circadian rhythm recording","journal":"Biochemical and Biophysical Research Communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, localization assay without direct binding or phosphorylation evidence for clock proteins","pmids":["28412365"],"is_preprint":false},{"year":2023,"finding":"VRK3 depletion in DMG-H3K27M cells causes G1 arrest, reduces phosphorylation of histone H3 at Ser10 and Ser28 (markers of chromatin condensation), and concomitantly decreases VRK1 protein levels, suggesting VRK3 supports chromatin condensation regulation partly through maintaining VRK1.","method":"siRNA knockdown, gene expression profiling, phospho-histone immunoblotting, cell cycle analysis","journal":"Frontiers in Oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, indirect evidence for histone phosphorylation link; no direct kinase assay on histones","pmids":["37886173"],"is_preprint":false}],"current_model":"VRK3 is a nuclear pseudokinase (catalytically inactive toward ATP per structural studies) that nevertheless retains limited kinase activity toward BAF/Ser4 via its N-terminal regulatory region; it primarily acts as a signaling scaffold that directly binds and activates the VHR dual-specificity phosphatase to suppress ERK activity in the nucleus, and this function is potentiated by CDK5-mediated phosphorylation of VRK3 at Ser108 and by nuclear HSP70 recruitment under stress conditions, while also influencing cell cycle progression and circadian clock protein localization."},"narrative":{"mechanistic_narrative":"VRK3 is a nuclear pseudokinase that functions primarily as a signaling scaffold to suppress ERK activity in the nucleus [PMID:19141289, PMID:16845380]. Its crystal structure shows a degraded active site that cannot bind ATP, with surface residues conserved for protein–protein interactions, consistent with a scaffolding rather than canonical catalytic role [PMID:19141289]. VRK3 directly binds the dual-specificity phosphatase VHR and enhances its phosphatase activity toward phospho-ERK independently of any kinase activity, forming a VHR–VRK3 complex that constitutes the phosphatase-active form regulating EGF-induced ERK signaling [PMID:16845380, PMID:18035061]. This VHR-activating function is potentiated by CDK5-mediated phosphorylation of VRK3 at Ser108 under oxidative stress, which increases VRK3 affinity for VHR and confers neuroprotection against H2O2-induced apoptosis [PMID:27346674], and by VRK3-dependent nuclear localization of HSP70, which itself enhances VHR activity through direct interaction to limit excitotoxic ERK activation [PMID:27941812]. Despite its degraded active site, VRK3 retains kinase activity toward the nuclear envelope protein BAF at Ser4 via an N-terminal regulatory region, driving BAF nucleo-cytoplasmic translocation and promoting cell cycle progression [PMID:25899223]. Beyond these characterized roles, links to cell cycle regulators, circadian clock protein localization, and chromatin condensation are documented but mechanistically limited in the available corpus [PMID:28927264, PMID:28412365, PMID:37886173].","teleology":[{"year":2006,"claim":"Established VRK3's principal function by showing it acts as a kinase-independent scaffold that activates the VHR phosphatase to suppress nuclear ERK, reframing a putative kinase as a phosphatase regulator.","evidence":"Reciprocal Co-IP and in vitro phosphatase assays with recombinant VRK3 and kinase-dead mutant","pmids":["16845380"],"confidence":"High","gaps":["Structural basis of the VRK3–VHR interaction not defined","Did not establish how VRK3 enhances VHR catalysis mechanistically"]},{"year":2007,"claim":"Confirmed the VHR–VRK3–ERK complex exists in native tissue and is specific to VHR over MKP3, linking the scaffold to physiological EGF-induced ERK signaling.","evidence":"Immunoprecipitation from tissue/embryo lysates and in vitro phosphatase assay with recombinant VRK3","pmids":["18035061"],"confidence":"Medium","gaps":["Single lab confirmation","Tissue-specific functional consequences not tested in vivo"]},{"year":2009,"claim":"Resolved why VRK3 lacks canonical kinase activity by showing a degraded, ATP-incompetent active site locked in a pseudoactive conformation, while surface conservation supports a protein-interaction role.","evidence":"X-ray crystallography of VRK3/VRK2 with active-site and conservation analysis","pmids":["19141289"],"confidence":"High","gaps":["Crystallized construct lacked the N-terminal regulatory region","Structure of VRK3 bound to partners (VHR) not determined"]},{"year":2015,"claim":"Demonstrated residual kinase activity toward BAF/Ser4 via an N-terminal region absent from the crystal, reconciling the pseudokinase structure with a catalytic output that drives BAF relocalization and cell cycle progression.","evidence":"In vitro kinase assay with phospho-specific detection, Ser4 mutagenesis, immunofluorescence, flow cytometry, siRNA","pmids":["25899223"],"confidence":"Medium","gaps":["Single lab; kinase activity not validated against structural data","How the N-terminal region confers catalysis is unresolved"]},{"year":2016,"claim":"Identified an upstream regulatory input by showing CDK5 phosphorylates VRK3 at Ser108 to boost VHR binding and ERK suppression, providing stress-dependent neuroprotection.","evidence":"In vitro CDK5 kinase assay, Co-IP, S108A mutant, siRNA in neurons","pmids":["27346674"],"confidence":"Medium","gaps":["Single lab","Whether Ser108 phosphorylation directly alters the VRK3–VHR interface is unknown"]},{"year":2016,"claim":"Extended the scaffold model by showing VRK3 promotes nuclear HSP70 localization, where HSP70 directly enhances VHR activity to dampen excitotoxic ERK signaling.","evidence":"Co-IP, subcellular fractionation, phosphatase assay, NLS-HSP70 rescue, VRK3-KO neurons","pmids":["27941812"],"confidence":"Medium","gaps":["Single lab","Mechanism by which VRK3 drives HSP70 nuclear import not defined"]},{"year":2017,"claim":"Broadened VRK3's cell cycle role through interactome capture of XRCC5 and CCNB1 and depletion phenotypes affecting S phase and G2/M transitions.","evidence":"AP-LC-MS/MS interactomics, biochemical confirmation, flow cytometry, siRNA in liver cancer cells","pmids":["28927264"],"confidence":"Low","gaps":["Interactome screen with only partial biochemical confirmation","Direct phosphorylation of XRCC5/CCNB1 by VRK3 not demonstrated"]},{"year":2017,"claim":"Implicated VRK3 in circadian regulation by showing it reduces nuclear clock-protein abundance and alters rhythm amplitude and period.","evidence":"RFP-tagged clock protein imaging, NLS-mutant VRK3, siRNA with bioluminescence recording","pmids":["28412365"],"confidence":"Low","gaps":["No direct binding or phosphorylation of clock proteins shown","Mechanism of nuclear clock-protein reduction unknown"]},{"year":2023,"claim":"Linked VRK3 to chromatin condensation and VRK1 maintenance in DMG-H3K27M cells, connecting its depletion to G1 arrest and reduced phospho-histone H3.","evidence":"siRNA knockdown, expression profiling, phospho-histone immunoblotting, cell cycle analysis","pmids":["37886173"],"confidence":"Low","gaps":["Indirect evidence; no direct histone kinase assay","Mechanism of VRK1 protein-level maintenance unresolved"]},{"year":null,"claim":"It remains unknown how VRK3 mechanistically activates VHR at the molecular level and whether its scaffold and residual-kinase functions are coordinated.","evidence":"No structural or reconstitution study of the VRK3–VHR active complex in the corpus","pmids":[],"confidence":"Low","gaps":["No structure of VRK3 bound to VHR","Coordination between BAF phosphorylation and ERK-suppression scaffold roles undefined","In vivo significance of cell cycle and circadian roles untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,4,5]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,5,7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,4,5]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,6]}],"complexes":[],"partners":["DUSP3","MAPK1","CDK5","HSPA1A","BANF1","XRCC5","CCNB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8IV63","full_name":"Serine/threonine-protein kinase VRK3","aliases":["Vaccinia-related kinase 3"],"length_aa":474,"mass_kda":52.9,"function":"Plays a role in the regulation of the cell cycle by phosphorylating the nuclear envelope protein barrier-to-autointegration factor/BAF that is required for disassembly and reassembly, respectively, of the nuclear envelope during mitosis (PubMed:25899223). Under normal physiological conditions, negatively regulates ERK activity along with VHR/DUSP3 phosphatase in the nucleus, causing timely and transient action of ERK. Stress conditions activate CDK5 which phosphorylates VRK3 to increase VHR phosphatase activity and suppress prolonged ERK activation that causes cell death (PubMed:27346674). For example, upon glutamate induction, promotes nuclear localization of HSP70/HSPA1A to inhibit ERK activation via VHR/DUSP3 phosphatase (PubMed:27941812)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q8IV63/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VRK3","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000105053","cell_line_id":"CID001303","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"big_aggregates","grade":2}],"interactors":[{"gene":"RCBTB2","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID001303","total_profiled":1310},"omim":[{"mim_id":"619771","title":"VRK SERINE/THREONINE KINASE 3; VRK3","url":"https://www.omim.org/entry/619771"},{"mim_id":"603811","title":"BARRIER-TO-AUTOINTEGRATION FACTOR 1; BANF1","url":"https://www.omim.org/entry/603811"},{"mim_id":"600183","title":"DUAL-SPECIFICITY PHOSPHATASE 3; DUSP3","url":"https://www.omim.org/entry/600183"},{"mim_id":"140550","title":"HEAT-SHOCK 70-KD PROTEIN 1A; HSPA1A","url":"https://www.omim.org/entry/140550"},{"mim_id":"123831","title":"CYCLIN-DEPENDENT KINASE 5; CDK5","url":"https://www.omim.org/entry/123831"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"testis","ntpm":128.9}],"url":"https://www.proteinatlas.org/search/VRK3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q8IV63","domains":[{"cath_id":"3.30.200.20","chopping":"155-188_197-234_242-259","consensus_level":"high","plddt":93.5719,"start":155,"end":259},{"cath_id":"1.10.510.10","chopping":"262-459","consensus_level":"high","plddt":96.769,"start":262,"end":459}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IV63","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IV63-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IV63-F1-predicted_aligned_error_v6.png","plddt_mean":79.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VRK3","jax_strain_url":"https://www.jax.org/strain/search?query=VRK3"},"sequence":{"accession":"Q8IV63","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8IV63.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8IV63/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IV63"}},"corpus_meta":[{"pmid":"19141289","id":"PMC_19141289","title":"Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site.","date":"2009","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/19141289","citation_count":148,"is_preprint":false},{"pmid":"16845380","id":"PMC_16845380","title":"Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16845380","citation_count":69,"is_preprint":false},{"pmid":"27941812","id":"PMC_27941812","title":"VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and Aβ accumulation via enhancement of ERK phosphatase VHR activity.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27941812","citation_count":25,"is_preprint":false},{"pmid":"27346674","id":"PMC_27346674","title":"Stress-induced nuclear translocation of CDK5 suppresses neuronal death by downregulating ERK activation via VRK3 phosphorylation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27346674","citation_count":23,"is_preprint":false},{"pmid":"25899223","id":"PMC_25899223","title":"Presumed pseudokinase VRK3 functions as a BAF kinase.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25899223","citation_count":22,"is_preprint":false},{"pmid":"18035061","id":"PMC_18035061","title":"VRK3-mediated inactivation of ERK signaling in adult and embryonic rodent tissues.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18035061","citation_count":21,"is_preprint":false},{"pmid":"28927264","id":"PMC_28927264","title":"Comparative Interactomes of VRK1 and VRK3 with Their Distinct Roles in the Cell Cycle of Liver Cancer.","date":"2017","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/28927264","citation_count":13,"is_preprint":false},{"pmid":"31324890","id":"PMC_31324890","title":"A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31324890","citation_count":12,"is_preprint":false},{"pmid":"37886173","id":"PMC_37886173","title":"VRK3 depletion induces cell cycle arrest and metabolic reprogramming of pontine diffuse midline glioma - H3K27 altered cells.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37886173","citation_count":4,"is_preprint":false},{"pmid":"28412365","id":"PMC_28412365","title":"Vaccinia-related kinase 3 (VRK3) sets the circadian period and amplitude by affecting the subcellular localization of clock proteins in mammalian cells.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28412365","citation_count":2,"is_preprint":false},{"pmid":"41893729","id":"PMC_41893729","title":"Emergence of Catalytic Activity in VRK3: Phosphoproteomic Insights into the Regulatory Network of a Former Pseudokinase.","date":"2026","source":"Proteomes","url":"https://pubmed.ncbi.nlm.nih.gov/41893729","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.27.672552","title":"Novel examples of NMD escape through alternative intronic polyadenylation","date":"2025-08-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.27.672552","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":7477,"output_tokens":2289,"usd":0.028383,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9392,"output_tokens":3175,"usd":0.063168,"stage2_stop_reason":"end_turn"},"total_usd":0.091551,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of VRK3 reveals it cannot bind ATP due to residue substitutions in the binding pocket, is locked in a pseudoactive conformation, and conserves surface residue interactions that play architectural roles; its active site is degraded while surface regions show high conservation suggesting key protein–protein interactions.\",\n      \"method\": \"X-ray crystallography of VRK3 and VRK2; structural comparison and sequence conservation analysis\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with detailed active-site analysis and comparative structural validation\",\n      \"pmids\": [\"19141289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"VRK3 directly binds the dual-specificity phosphatase VHR and enhances its phosphatase activity toward phospho-ERK in the nucleus, thereby suppressing ERK activation; this enhancement is independent of VRK3's kinase activity, placing VRK3 as a phosphatase-activating scaffold upstream of ERK inactivation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase activity assays with recombinant VRK3, kinase-dead mutant analysis\",\n      \"journal\": \"Nature Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vitro phosphatase assay with kinase-dead mutant, replicated in subsequent work\",\n      \"pmids\": [\"16845380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"VRK3 forms a protein complex with VHR and ERK in rodent tissues including testis; recombinant VRK3 added to tissue lysates specifically enhances VHR phosphatase activity (but not MKP3 activity), and the VHR–VRK3 complex represents the phosphatase-active form that regulates EGF-induced ERK signaling.\",\n      \"method\": \"Immunoprecipitation from adult tissue and embryo lysates, in vitro phosphatase activity assay with recombinant VRK3, co-localization\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and in vitro phosphatase assay, single lab confirming earlier finding with tissue specificity data\",\n      \"pmids\": [\"18035061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VRK3 phosphorylates the nuclear envelope protein BAF (Barrier-to-Autointegration Factor) on Ser4; this kinase activity depends on VRK3's N-terminal regulatory region absent from its crystal structure. VRK3-mediated BAF phosphorylation causes translocation of BAF from nucleus to cytoplasm, and VRK3 expression is elevated during interphase where it promotes cell cycle progression.\",\n      \"method\": \"In vitro kinase assay with phospho-specific detection, site-directed mutagenesis (Ser4), immunofluorescence localization, cell cycle analysis by flow cytometry, siRNA depletion\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay with mutagenesis and localization readout, single lab\",\n      \"pmids\": [\"25899223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CDK5 phosphorylates VRK3 at Ser108 under oxidative stress; phosphorylated VRK3 has increased affinity for VHR phosphatase, leading to enhanced VHR-mediated dephosphorylation of ERK and neuroprotection against H2O2-induced apoptosis. A non-phosphorylatable VRK3 mutant (S108A) fails to attenuate apoptosis.\",\n      \"method\": \"In vitro kinase assay (CDK5 phosphorylating VRK3), co-immunoprecipitation, phospho-specific antibodies, VRK3 mutant overexpression, siRNA knockdown in neurons\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay plus mutagenesis and functional readout, single lab\",\n      \"pmids\": [\"27346674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VRK3 facilitates nuclear localization of HSP70 after glutamate-induced excitotoxicity; nuclear HSP70 enhances VHR phosphatase activity via direct protein–protein interaction (not chaperone activity), thereby suppressing excessive ERK activation. VRK3-deficient neurons showed impaired HSP70 nuclear localization and increased vulnerability to glutamate-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, phosphatase activity assay, siRNA knockdown, NLS-fused HSP70 rescue experiments, VRK3-KO neurons\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical methods including Co-IP and phosphatase assay plus genetic KO confirmation, single lab\",\n      \"pmids\": [\"27941812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"VRK3 interacts with and regulates phosphorylation of XRCC5 (Ku80) and CCNB1 (Cyclin B1) as identified by affinity purification–mass spectrometry; VRK3 depletion in liver cancer cells affects S phase progression and G2/M entry and exit.\",\n      \"method\": \"Affinity purification coupled to LC-MS/MS interactomics, biochemical confirmation of interactions, flow cytometry cell cycle analysis, siRNA knockdown\",\n      \"journal\": \"Molecules and Cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — interactome screen with partial biochemical confirmation, single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"28927264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Ectopic expression of VRK3 reduces nuclear presence of CRY1, CRY2, PER2, and BMAL1 (but not CLOCK) in mammalian cells; a nuclear localization sequence mutant of VRK3 attenuates this effect. siRNA-mediated knockdown of VRK3 reduces amplitude and lengthens the period of cellular circadian bioluminescence rhythms.\",\n      \"method\": \"Fluorescence imaging of RFP-tagged clock proteins upon VRK3 overexpression, NLS-mutant VRK3, siRNA knockdown with bioluminescence circadian rhythm recording\",\n      \"journal\": \"Biochemical and Biophysical Research Communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, localization assay without direct binding or phosphorylation evidence for clock proteins\",\n      \"pmids\": [\"28412365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"VRK3 depletion in DMG-H3K27M cells causes G1 arrest, reduces phosphorylation of histone H3 at Ser10 and Ser28 (markers of chromatin condensation), and concomitantly decreases VRK1 protein levels, suggesting VRK3 supports chromatin condensation regulation partly through maintaining VRK1.\",\n      \"method\": \"siRNA knockdown, gene expression profiling, phospho-histone immunoblotting, cell cycle analysis\",\n      \"journal\": \"Frontiers in Oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, indirect evidence for histone phosphorylation link; no direct kinase assay on histones\",\n      \"pmids\": [\"37886173\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VRK3 is a nuclear pseudokinase (catalytically inactive toward ATP per structural studies) that nevertheless retains limited kinase activity toward BAF/Ser4 via its N-terminal regulatory region; it primarily acts as a signaling scaffold that directly binds and activates the VHR dual-specificity phosphatase to suppress ERK activity in the nucleus, and this function is potentiated by CDK5-mediated phosphorylation of VRK3 at Ser108 and by nuclear HSP70 recruitment under stress conditions, while also influencing cell cycle progression and circadian clock protein localization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"VRK3 is a nuclear pseudokinase that functions primarily as a signaling scaffold to suppress ERK activity in the nucleus [#0, #1]. Its crystal structure shows a degraded active site that cannot bind ATP, with surface residues conserved for protein\\u2013protein interactions, consistent with a scaffolding rather than canonical catalytic role [#0]. VRK3 directly binds the dual-specificity phosphatase VHR and enhances its phosphatase activity toward phospho-ERK independently of any kinase activity, forming a VHR\\u2013VRK3 complex that constitutes the phosphatase-active form regulating EGF-induced ERK signaling [#1, #2]. This VHR-activating function is potentiated by CDK5-mediated phosphorylation of VRK3 at Ser108 under oxidative stress, which increases VRK3 affinity for VHR and confers neuroprotection against H2O2-induced apoptosis [#4], and by VRK3-dependent nuclear localization of HSP70, which itself enhances VHR activity through direct interaction to limit excitotoxic ERK activation [#5]. Despite its degraded active site, VRK3 retains kinase activity toward the nuclear envelope protein BAF at Ser4 via an N-terminal regulatory region, driving BAF nucleo-cytoplasmic translocation and promoting cell cycle progression [#3]. Beyond these characterized roles, links to cell cycle regulators, circadian clock protein localization, and chromatin condensation are documented but mechanistically limited in the available corpus [#6, #7, #8].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established VRK3's principal function by showing it acts as a kinase-independent scaffold that activates the VHR phosphatase to suppress nuclear ERK, reframing a putative kinase as a phosphatase regulator.\",\n      \"evidence\": \"Reciprocal Co-IP and in vitro phosphatase assays with recombinant VRK3 and kinase-dead mutant\",\n      \"pmids\": [\"16845380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the VRK3\\u2013VHR interaction not defined\",\n        \"Did not establish how VRK3 enhances VHR catalysis mechanistically\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Confirmed the VHR\\u2013VRK3\\u2013ERK complex exists in native tissue and is specific to VHR over MKP3, linking the scaffold to physiological EGF-induced ERK signaling.\",\n      \"evidence\": \"Immunoprecipitation from tissue/embryo lysates and in vitro phosphatase assay with recombinant VRK3\",\n      \"pmids\": [\"18035061\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab confirmation\",\n        \"Tissue-specific functional consequences not tested in vivo\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved why VRK3 lacks canonical kinase activity by showing a degraded, ATP-incompetent active site locked in a pseudoactive conformation, while surface conservation supports a protein-interaction role.\",\n      \"evidence\": \"X-ray crystallography of VRK3/VRK2 with active-site and conservation analysis\",\n      \"pmids\": [\"19141289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Crystallized construct lacked the N-terminal regulatory region\",\n        \"Structure of VRK3 bound to partners (VHR) not determined\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated residual kinase activity toward BAF/Ser4 via an N-terminal region absent from the crystal, reconciling the pseudokinase structure with a catalytic output that drives BAF relocalization and cell cycle progression.\",\n      \"evidence\": \"In vitro kinase assay with phospho-specific detection, Ser4 mutagenesis, immunofluorescence, flow cytometry, siRNA\",\n      \"pmids\": [\"25899223\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab; kinase activity not validated against structural data\",\n        \"How the N-terminal region confers catalysis is unresolved\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified an upstream regulatory input by showing CDK5 phosphorylates VRK3 at Ser108 to boost VHR binding and ERK suppression, providing stress-dependent neuroprotection.\",\n      \"evidence\": \"In vitro CDK5 kinase assay, Co-IP, S108A mutant, siRNA in neurons\",\n      \"pmids\": [\"27346674\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab\",\n        \"Whether Ser108 phosphorylation directly alters the VRK3\\u2013VHR interface is unknown\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended the scaffold model by showing VRK3 promotes nuclear HSP70 localization, where HSP70 directly enhances VHR activity to dampen excitotoxic ERK signaling.\",\n      \"evidence\": \"Co-IP, subcellular fractionation, phosphatase assay, NLS-HSP70 rescue, VRK3-KO neurons\",\n      \"pmids\": [\"27941812\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single lab\",\n        \"Mechanism by which VRK3 drives HSP70 nuclear import not defined\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Broadened VRK3's cell cycle role through interactome capture of XRCC5 and CCNB1 and depletion phenotypes affecting S phase and G2/M transitions.\",\n      \"evidence\": \"AP-LC-MS/MS interactomics, biochemical confirmation, flow cytometry, siRNA in liver cancer cells\",\n      \"pmids\": [\"28927264\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Interactome screen with only partial biochemical confirmation\",\n        \"Direct phosphorylation of XRCC5/CCNB1 by VRK3 not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Implicated VRK3 in circadian regulation by showing it reduces nuclear clock-protein abundance and alters rhythm amplitude and period.\",\n      \"evidence\": \"RFP-tagged clock protein imaging, NLS-mutant VRK3, siRNA with bioluminescence recording\",\n      \"pmids\": [\"28412365\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No direct binding or phosphorylation of clock proteins shown\",\n        \"Mechanism of nuclear clock-protein reduction unknown\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked VRK3 to chromatin condensation and VRK1 maintenance in DMG-H3K27M cells, connecting its depletion to G1 arrest and reduced phospho-histone H3.\",\n      \"evidence\": \"siRNA knockdown, expression profiling, phospho-histone immunoblotting, cell cycle analysis\",\n      \"pmids\": [\"37886173\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Indirect evidence; no direct histone kinase assay\",\n        \"Mechanism of VRK1 protein-level maintenance unresolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how VRK3 mechanistically activates VHR at the molecular level and whether its scaffold and residual-kinase functions are coordinated.\",\n      \"evidence\": \"No structural or reconstitution study of the VRK3\\u2013VHR active complex in the corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structure of VRK3 bound to VHR\",\n        \"Coordination between BAF phosphorylation and ERK-suppression scaffold roles undefined\",\n        \"In vivo significance of cell cycle and circadian roles untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 4, 5]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 5, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 4, 5]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DUSP3\", \"MAPK1\", \"CDK5\", \"HSPA1A\", \"BANF1\", \"XRCC5\", \"CCNB1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}